Blincyto FDA Approval History
FDA Approved: Yes (First approved December 3, 2014)
Brand name: Blincyto
Generic name: blinatumomab
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Acute Lymphoblastic Leukemia
Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and minimal residual disease (MRD)-positive B-cell precursor ALL.
Development timeline for Blincyto
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.